Biomarin

9 Notable Biotechs Presenting At This Year's ASH Meeting
Yahoo
Tue, 11/7/17 - 09:56 am
ASH
Bluebird Bio
LentiGlobin
Ziopharm Oncology
Bellicum
BPX-501
Spark Therapeutics
SPK-8011
Biomarin
BMN 270
Juno Therapeutics
CAR-T
Novartis
Geron
imetelstat
Immunogen
IMGN632
IMGN779
With ‘breakthrough’ status and a handy nickname, BioMarin plots speedy PhIII for gene therapy
Endpoints
Sun, 10/29/17 - 10:04 am
Biomarin
gene therapy
BMN 270
hemophilia A
BioMarin says the FDA game clock now ticking on their blockbuster hopeful pegvaliase
Endpoints
Wed, 08/30/17 - 10:01 am
Biomarin
FDA
pegvaliase
PDUFA
Biomarin announces new investments in Ireland
GoInPharma
Sat, 08/12/17 - 11:47 am
Biomarin
Ireland
BioMarin may have lost the battle in DMD rivalry, but it won a $35M argument with Sarepta
Endpoints
Tue, 07/18/17 - 09:28 am
Biomarin
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
BioMarin, Spark, raising the stakes for hemophilia
BioPharma Dive
Wed, 07/12/17 - 02:48 pm
Biomarin
Spark Therapeutics
hemophilia
BMN 270
SPK-9001
gene therapy
BioMarin CEO says 'the system will have to determine' the worth of its new $702,000 drug
CNBC
Sun, 04/30/17 - 12:51 pm
Biomarin
Brineura
drug pricing
Batten disease
4 Drug Stocks With Big News Coming in April
Motley Fool
Tue, 04/4/17 - 12:11 am
Neurocrine
Incyte
Eli Lilly
Biomarin
Ingrezza
baricitinib
Brineura
BioMarin Pharmaceutical Inc. Logs a Combined Blockbuster
Motley Fool
Sat, 02/25/17 - 03:19 pm
Biomarin
earnings
Vimizim
Kuvan
Naglazyme
BioMarin sues to stop generic version of its $90K-a-year drug
Bizjournals.com
Mon, 02/6/17 - 10:04 pm
Biomarin
generics
Kuvan
Dr Reddy's
Biotech Investing: 3 Bold Predictions for 2017
Motley Fool
Fri, 01/6/17 - 09:47 am
biotech
Incyte
Biogen
Biomarin
Gilead Sciences
Illumina
7 of the Most Shocking Biotech Pipeline Blowups of 2016
Motley Fool
Sun, 12/4/16 - 12:37 pm
biotech
Alnylam
revusiran
Clovis Oncology
rociletinib
Celldex Therapeutics
Rintega
Eli Lilly
solanezumab
Novavax
RSV-F
Arrowhead
ARC-520
ARC-521
ARC-AAT
Biomarin
drisapersen
BioMarin’s Disappointing 3Q16 Earnings
Market Realist
Mon, 10/31/16 - 06:34 pm
Biomarin
earnings
Sarepta Therapeutics' Greatest Threat: Anthem?
Motley Fool
Mon, 10/17/16 - 11:41 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 5
Biomarin
Anthem
FDA’s controversial OK for eteplirsen spurs second thoughts for a rejected rival at BioMarin
Endpoints
Thu, 10/13/16 - 03:33 pm
FDA
eteplirsen
Duchenne Muscular Dystrophy
Biomarin
Sarepta Therapeutics
3 Biotechs Most Likely to Be Acquired
Motley Fool
Tue, 10/11/16 - 09:45 pm
biotech
M&A
Incyte
Biomarin
Biogen
After Sarepta win, BioMarin appeals DMD patent ruling
BioPharma Dive
Fri, 09/23/16 - 09:35 am
Sarepta Therapeutics
Biomarin
patents
Duchenne Muscular Dystrophy
eteplirsen
Kyndrisa
BioMarin hits snag with latest rare disease drug
BioPharma Dive
Wed, 09/7/16 - 08:34 pm
Biomarin
Brineura
FDA
CLN2 disease
3 Biotech Stocks Could Be the Next Big Takeover Targets
24/7 Wall St
Wed, 08/31/16 - 09:20 am
biotech
M&A
Biomarin
Incyte
Tesaro
4 Biotech Buyout Targets for Gilead, Sanofi After Medivation Miss
Barron's
Tue, 08/23/16 - 11:11 am
biotech
M&A
Gilead Sciences
Sanofi
Medivation
Incyte
Biomarin
Tesaro
Seattle Genetics

Pages